TY - JOUR ID - 80972 TI - Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Lian, Haiwei AU - Su, Min AU - Zhu, Yijie AU - Zhou, Yun AU - Soomro, Shahid Hussain AU - Fu, Hui AD - Department of Human Anatomy, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei, P.R, China. AD - Department of Gynaecology, Renmin Hospital, Wuhan University, Wuhan, Hubei, P.R. China. Y1 - 2019 PY - 2019 VL - 20 IS - 1 SP - 23 EP - 32 KW - Protein kinase CK2 KW - solid tumors KW - Hematological tumors KW - CX-4945 KW - CIBG-300 DO - 10.31557/APJCP.2019.20.1.23 N2 - The Protein kinase CK2 (formerly known as casein kinase 2) is a highly conserved serine/ threonine kinaseoverexpressed in various human carcinomas and its high expression often correlates with poor prognosis. CK2 proteinis localized in the nucleus of many tumor cells and correlates with clinical features in many cases. Increased expressionof CK2 in mice results in the development of various types of carcinomas (both solids and blood related tumors, suchas (breast carcinoma, lymphoma, etc), which reveals its carcinogenic properties. CK2 plays essential roles in many keybiological processes related to carcinoma, including cell apoptosis, DNA damage responses and cell cycle regulation.CK2 has become a potential anti-carcinoma target. Various CK2 inhibitors have been developed with anti-neoplasticproperties against a variety of carcinomas. Some CK2 inhibitors have showed good results in in vitro and pre-clinicalmodels, and have even entered in clinical trials. This article will review effects of CK2 and its inhibitors on commoncarcinomas in in vitro and pre-clinical studies. UR - https://journal.waocp.org/article_80972.html L1 - https://journal.waocp.org/article_80972_7978cc99e1b590738ad7179e64cde176.pdf ER -